TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2483580

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 7027430

Group type: EXPERIMENTAL
Intervention: 3 g of salsalate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 3 to 5 g of salsalate daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: soluble, intravenous or enteric-coated forms of acetylsalicylates
Number of subjects: 42
Study: 30621717

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium 110/50 μg once daily (IND/GLY)
Number of subjects: 3362

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone 50/500 twice daily (SFC)
Number of subjects: 3362
Study: 27861991

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks (Q2W)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly (QM)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Evolocumab (various doses from 7-420 mg SC)
Number of subjects: 101
Study: 25651476

Group type: EXPERIMENTAL
Intervention: Ibogaine (20 mg) with paroxetine pretreatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 21
Study: 24335445

Group type: EXPERIMENTAL
Intervention: AZD9773 low dose (250 U/kg followed by 50 U/kg every 12 hours)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: AZD9773 high dose (500 U/kg followed by 100 U/kg every 12 hours)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: AZD9773 low dose
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: AZD9773 high dose
Number of subjects: 300

Group type: COMPARATOR
Intervention: AZD9773 and placebo
Number of subjects: 300
Study: 22659487

Group type: EXPERIMENTAL
Intervention: Formoterol (12 μg bid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg od)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 20226558

Group type: EXPERIMENTAL
Intervention: Long-term diagnosed diabetes
Number of subjects: 4060

Group type: COMPARATOR
Intervention: Incident diagnosed diabetes
Number of subjects: 4060
Study: 18518675

Group type: EXPERIMENTAL
Intervention: Manual measurement technique
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Computer-assisted measurements using QMA software
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of both techniques
Number of subjects: 100

Group type: COMPARATOR
Intervention: Disagreement cases
Number of subjects: 100
Study: 15772571

Group type: EXPERIMENTAL
Intervention: EPT every day (0.625 mg of conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate)
Number of subjects: 99

Group type: COMPARATOR
Intervention: EPT every other day (0.625 mg of conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: EPT every day
Number of subjects: 99
Study: 11955393

Group type: EXPERIMENTAL
Intervention: Single 80 mg epirubicin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 40 mg consecutive epirubicin
Number of subjects: 47

Group type: COMPARATOR
Intervention: 40 mg consecutive mitomycin C
Number of subjects: 47
Study: 10544418

Group type: EXPERIMENTAL
Intervention: Roller On (motion of the artificial bed partner)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Roller Off (stationary roller)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Roller On
Number of subjects: 24
Study: 7588490

Group type: EXPERIMENTAL
Intervention: Sulfuric acid aerosol preexposure (100 micrograms/m3) followed by ozone exposure (0.08, 0.12, or 0.18 ppm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium chloride aerosol preexposure (control) followed by ozone exposure (0.08, 0.12, or 0.18 ppm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined analysis of normal and asthmatic subjects
Number of subjects: 60
Study: 2148148

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 42

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 42
Study: 6750929

Group type: EXPERIMENTAL
Intervention: 99m‐Tc‐MDP or 99m‐Tc‐DTPA administration
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Alpha- and betamimetics, cholinesterase inhibitors
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 67
Study: 30732459

Group type: EXPERIMENTAL
Intervention: Program A (two months without acute analgesics or migraine medications)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Program B (two months with acute medications restricted to two days/week)
Number of subjects: 72
Study: 28533058

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No Music Therapy
Number of subjects: 82
Study: 25900643

Group type: EXPERIMENTAL
Intervention: 1000 mg intravenous iron isomaltoside 1000 administered perioperatively by infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24494291

Group type: EXPERIMENTAL
Intervention: Longhu Jiaozhan manipulation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Even manipulation (control group)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both methods of acupuncture
Number of subjects: 62
Study: 21627398

Group type: COMPARATOR
Intervention: Standard triple drug therapy (omeprazole, clarithromycin, and amoxicillin for 10 days)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sequential therapy (omeprazole and amoxicillin for the first 5 days followed by omeprazole, clarithromycin, and amoxicillin for the next 5 days)
Number of subjects: 73
Study: 19751435

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori infection
Number of subjects: 2361
Study: 17355820

Group type: EXPERIMENTAL
Intervention: Passive graft perfusion (PGP, n = 15) during anastomosis and immediate graft perfusion after distal anastomosis.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Passive graft perfusion (PGP, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No graft perfusion (NGP, n = 15)
Number of subjects: 30
Study: 15211234

Group type: EXPERIMENTAL
Intervention: Pristinamycin 3 G daily for 4 days
Number of subjects: 476

Group type: COMPARATOR
Intervention: Co-amoxiclav 2 G daily for 8 days
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Pristinamycin
Number of subjects: 476

Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 476
Study: 11683127

Group type: EXPERIMENTAL
Intervention: Lasoprol (test formulation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lanzor (reference formulation)
Number of subjects: 12
Study: 9645593

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 400 microg twice a day
Number of subjects: 24
Study: 7840912

Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 180
Study: 3277587

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Clindamycin and Gentamicin
Number of subjects: 57
Study: 30059785

Group type: EXPERIMENTAL
Intervention: Calfactant (1 or 2 doses)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Calfactant
Number of subjects: 43
Study: 27549242

Group type: EXPERIMENTAL
Intervention: Ramucirumab (n = 45)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (n = 48)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Ramucirumab (n = 44)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (n = 47)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Ramucirumab (n = 20)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 93
Study: 24273137

Group type: EXPERIMENTAL
Intervention: ICIQ‐UI SF
Number of subjects: 0
Study: 24244725

Group type: EXPERIMENTAL
Intervention: Migraineurs
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-migraine controls
Number of subjects: 25
Study: 21846401

Group type: EXPERIMENTAL
Intervention: Integrated approach to care based on the chronic care model
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Shared decision making intervention
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: School based care intervention through case management
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Usual care control group without electronic medical record (EMR)
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Control group with EMR with decision support, asthma action plans, and population reports at baseline
Number of subjects: 30000
Study: 18234120

Group type: EXPERIMENTAL
Intervention: Olanzapine (1.25 mg/day for 3 days, 2.5 mg/day for 4 days, 5 mg/day for 1 week, then 7.5 mg/day for 10 weeks, followed by tapering over 2 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 15740485

Group type: EXPERIMENTAL
Intervention: Fiber free (FF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insoluble fiber (IF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mixed fiber (MF)
Number of subjects: 8
Study: 12431971

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 190
Study: 10486668

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure target < or = 80 mmHg (n = 6,262)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure decrease from 90 to 80 mmHg in diabetic population
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid in well-controlled blood pressure population
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Diastolic blood pressure target < or = 85 mmHg (n = 6,264)
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Diastolic blood pressure target < or = 90 mmHg (n = 6,264)
Number of subjects: 18790
Study: 8701855

Group type: EXPERIMENTAL
Intervention: Flosequinan 100 mg once daily
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Flosequinan 75 mg twice daily
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 1876437

Group type: EXPERIMENTAL
Intervention: ICS 205-930 (15 mg daily)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: ICS 205-930 (25 mg daily)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: ICS 205-930 (50 mg daily)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 6639234

Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 14
Study: 31790519

Group type: EXPERIMENTAL
Intervention: Depression screening after acute coronary syndromes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no depression screening)
Number of subjects: 0
Study: 29243411

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle aspiration (EUS-FNA)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB)
Number of subjects: 23
Study: 27101760

Group type: EXPERIMENTAL
Intervention: Choline-enriched structured lipid (LYM-X-SORB)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 23590972

Group type: EXPERIMENTAL
Intervention: Separation from a parent in childhood
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Death of a parent in childhood
Number of subjects: 781
Study: 22416798

Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir monotherapy
Number of subjects: 156

Group type: COMPARATOR
Intervention: darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors (triple therapy)
Number of subjects: 156
Study: 20848004

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RMGIC) (Vitremer™, 3M ESPE)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Conventional light-cure, resin-based fissure sealant (LCRB) (Fluoroshield®, Dentsply Caulk)
Number of subjects: 320
Study: 16402257

Group type: EXPERIMENTAL
Intervention: Colon dissection approach
Number of subjects: 21

Group type: COMPARATOR
Intervention: Endoluminal view
Number of subjects: 21
Study: 12621364

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mannan-binding lectin (MBL) levels
Number of subjects: 0
Study: 10781119

Group type: EXPERIMENTAL
Intervention: LMA‐High (fully inflated cuff)
Number of subjects: 160

Group type: COMPARATOR
Intervention: LMA‐Low (semi‐inflated cuff)
Number of subjects: 160
Study: 8978881

Group type: EXPERIMENTAL
Intervention: Low fat, increased fruit/vegetable/grain product intervention
Number of subjects: 2208

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2208
Study: 1297667

Group type: EXPERIMENTAL
Intervention: Vaginal resection involving 2/3rds of the vagina
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (vaginal resection not involving 2/3rds of the vagina)
Number of subjects: 154
Study: 4006483

Group type: EXPERIMENTAL
Intervention: Beta-Blocker Heart Attack Trial (BHAT)
Number of subjects: 3837

Group type: EXPERIMENTAL
Intervention: Hypertension Detection and Follow-up Program (HDFP)
Number of subjects: 3837
Study: 31078823

Group type: EXPERIMENTAL
Intervention: Direct placement
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional placement
Number of subjects: 60
Study: 28980306

Group type: EXPERIMENTAL
Intervention: 50% oxygen inhalation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Air inhalation
Number of subjects: 120
Study: 27002448

Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice daily) and Erlotinib (75 mg daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 24910380

Group type: EXPERIMENTAL
Intervention: Self-directed exercise program
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Self-administered stress management program
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Both self-directed exercise and stress management programs
Number of subjects: 711

Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 711
Study: 22326977

Group type: EXPERIMENTAL
Intervention: Intravenous sodium valproate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous phenobarbital
Number of subjects: 60
Study: 19473858

Group type: EXPERIMENTAL
Intervention: articaine 20mg/ml
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: articaine 40mg/ml
Number of subjects: 150

Group type: COMPARATOR
Intervention: lidocaine 20mg/ml
Number of subjects: 150
Study: 17988906

Group type: EXPERIMENTAL
Intervention: Collar graft
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard dacron graft
Number of subjects: 40
Study: 16202957

Group type: EXPERIMENTAL
Intervention: Analgesia or sedation during reduction of incarcerated inguinal hernia; 96.7% (245/253) of responders reported using analgesia or sedation.
Number of subjects: 331

Group type: COMPARATOR
Intervention: Intravenous drugs used by pediatric surgeons; they were more likely to use intravenous drugs compared to pediatric emergency physicians.
Number of subjects: 331

Group type: COMPARATOR
Intervention: Clinically related variables for pediatric emergency physicians; more important for PEPs than PS for analgesia and sedation.
Number of subjects: 331
Study: 11898704

Group type: EXPERIMENTAL
Intervention: Vaginal solution 40 mg of phentolamine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Oral tablet 40 mg of phentolamine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9895068

Group type: EXPERIMENTAL
Intervention: Sympathectomy (lidocaine injection into the brachial plexus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution injection (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tcPCO2
Number of subjects: 0
Study: 7675689

Group type: EXPERIMENTAL
Intervention: Belief and information interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2048663

Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7297411

Group type: EXPERIMENTAL
Intervention: Naltrexone (dosage schedule used for opiate-dependent persons)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Naltrexone (50 or 100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Naltrexone placebo
Number of subjects: 20
Study: 30576726

Group type: EXPERIMENTAL
Intervention: Memory-game with images of vegetables (n=47)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (memory-game with non-food items, n=53)
Number of subjects: 100
Study: 28042930

Group type: EXPERIMENTAL
Intervention: 3D-group (three days sick leave)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7D-group (seven days sick leave)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3D-group
Number of subjects: 0

Group type: COMPARATOR
Intervention: 7D-group
Number of subjects: 0
Study: 25846055

Group type: EXPERIMENTAL
Intervention: Delayed-release 6-mercaptopurine (DR-6MP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Purinethol (systemically delivered 6-mercaptopurine)
Number of subjects: 70
Study: 24083231

Group type: EXPERIMENTAL
Intervention: One set of resistance training (n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Three sets of resistance training (n = 8)
Number of subjects: 16
Study: 21856517

Group type: EXPERIMENTAL
Intervention: Counseling sessions on breastfeeding directed toward both mother and grandmother (cohabitating group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counseling sessions on breastfeeding directed only toward mother (not cohabitating group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (mother and grandmother not cohabitating, without intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (mother and grandmother cohabitating, without intervention)
Number of subjects: 0
Study: 20025364

Group type: EXPERIMENTAL
Intervention: SM plus strategy increase (SI)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: SM plus alcohol reduction (AR)
Number of subjects: 177

Group type: COMPARATOR
Intervention: SM control (SM)
Number of subjects: 177
Study: 17088500

Group type: EXPERIMENTAL
Intervention: Sustained sadness state
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Neutral state
Number of subjects: 14
Study: 12775457

Group type: EXPERIMENTAL
Intervention: Patients with myocardial infarction (MI)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patients with ventricular tachycardia (VT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 50
Study: 11044647

Group type: EXPERIMENTAL
Intervention: Information provided to patients regarding clinical trial participation
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Method of treatment allocation
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Time for decision-making
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Satisfaction with decision to participate
Number of subjects: 299
Study: 9084897

Group type: EXPERIMENTAL
Intervention: 5% CO2 inhalation with epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5% CO2 inhalation with saline infusions
Number of subjects: 0
Study: 8471439

Group type: EXPERIMENTAL
Intervention: Cooper type regimens containing doxorubicin hydrochloride (dox)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cooper type regimens without doxorubicin (replaced by one or more compounds)
Number of subjects: 0
Study: 3545034

Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Molsidomine (8 mg/day)
Number of subjects: 41
Study: 31034730

Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Number of subjects: 44

Group type: COMPARATOR
Intervention: Caudal block
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 29105211

Group type: EXPERIMENTAL
Intervention: Parent-focused family-based treatment (PFT)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Conjoint family-based treatment (FBT)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Maternal expressed emotion (EE)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Paternal expressed emotion (EE)
Number of subjects: 153
Study: 25751130

Group type: EXPERIMENTAL
Intervention: Beck Scale for Suicide Ideation (21 items)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Quality of Life (19 items)
Number of subjects: 301
Study: 24521561

Group type: EXPERIMENTAL
Intervention: Ancient wheat products (bread, pasta, biscuits and crackers) for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Modern wheat products (bread, pasta, biscuits and crackers) for 6 weeks
Number of subjects: 20
Study: 22901350

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Agomelatine (in severe patients)
Number of subjects: 227
Study: 20568829

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sugammadex 32 mg/kg alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sugammadex 32 mg/kg with rocuronium 1.2 mg/kg
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sugammadex 32 mg/kg with vecuronium 0.1 mg/kg
Number of subjects: 84
Study: 18334007

Group type: EXPERIMENTAL
Intervention: Weekly topotecan (4 mg/m(2))
Number of subjects: 39
Study: 15681250

Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 30
Study: 12105829

Group type: EXPERIMENTAL
Intervention: EUS staging
Number of subjects: 80

Group type: COMPARATOR
Intervention: CT staging
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EUS FNA
Number of subjects: 80
Study: 12205257

Group type: EXPERIMENTAL
Intervention: HOPE-ROP infants
Number of subjects: 136

Group type: COMPARATOR
Intervention: STOP-ROP infants
Number of subjects: 136
Study: 9713056

Group type: EXPERIMENTAL
Intervention: Nd:YLF ps laser for iridectomies (n=53)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nd:YLF ps laser for capsulotomies (n=9)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nd:YAG ns laser for capsulotomies (n=10)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nd:YAG ns laser for iridotomies (n=20)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nd:YLF ps laser for vitreoretinal applications (n=2)
Number of subjects: 70